BRCA1 and neoplasm: In the largest cohort of patients with mCRPC (N = 3334 plasma samples), including patients from TRITON2 and TRITON3, 94% of patients had detectable plasma ctDNA, and a high level of concordance was seen (>90%) between plasma and tissue identification of BRCA1/2 mutations, with 93% of mutations identified in tumor tissue detected also in plasma (67/72 patients with BRCA1/2 mutations) [22].